Today approximately 40% of the world's population mostly those living in the world's poorest countries is at risk of malaria. The disease was once more widespread but it was successfully eliminated from many countries with temperate climates during the mid 20th century. Today malaria is found throughout the tropical and sub-tropical regions of the world and causes more than 300 million acute illnesses and at least one million deaths annually.But here's the worst of it:
Malaria kills an African child every 30 seconds. Many children who survive an episode of severe malaria may suffer from learning impairments or brain damage. Pregnant women and their unborn children are also particularly vulnerable to malaria, which is a major cause of perinatal mortality, low birth weight and maternal anaemia.Kids.
On a purely practical level, the most malignant (P. falciparum) cases develop within three months of leaving the malaria region, while the forms transmitted by P. vivax and P. ovale may not appear until three years later.This is one the insidious aspects of the disease. Humans serve as hosts, infecting other mosquitos for some period of time before becoming aware that they are infected. This greatly aids in the spreading of the epidemic.
The actual attacks of malaria develop when the red blood corpuscles burst, releasing a mass of parasites into the blood. The attacks do not begin until a sufficient number of blood corpuscles have been infected with parasites.As you can imagine, those who have the least immunity to malaria are most affected by the most malignant form....young children. But here's the real stumper. Malaria is easily preventable and is treatable. The obstacles to solving the malaria problem are the usual suspects: money, politics, and ignorance.
What are the characteristics of a malaria attack?
* Fever and shivering. The attack begins with fever, with the temperature rising as high as 40ºC and falling again over a period of several hours.
* A poor general condition, feeling unwell and having headaches like influenza.
* Diarrhoea, nausea and vomiting often occur as well.
When the temperature drops, the patient often sweats profusely and feels much better. Then the same day, or one to two days later, further attacks occur with feeling generally unwell, high temperature and so on.
The attacks diminish in the course of a number of weeks if the patient develops the ability to resist the malaria parasite. But if proper treatment is given, the fever and parasites can disappear within a few days.
...
In malignant malaria the illness may evolve with a number of complications:
* low blood pressure (hypotension)
* kidney failure
* possible haemorrhage (bleeding)
* effects on the liver (eg infectious jaundice)
* shock and coma may also develop
* the condition may prove fatal.
...
Malignant malaria can affect the brain and the rest of the central nervous system. It is characterised by changes in the level of consciousness, convulsions and paralysis.
According to the [WHO] report, malaria slows economic growth in Africa by up to 1.3% each year. This slowdown in economic growth due to malaria is over and above the more readily observed short run costs of the disease. Since sub-Saharan Africa's GDP is around $300 billion, the short-term benefits of malaria control can reasonably be estimated at between $3 billion and $12 billion per year.Of course, the problems of poverty are a part of the cycle of malaria. More malaria equals more poverty which equals more poverty.
...
The report also finds that:
* Malaria-free countries average three times higher GDP per person than malarious countries, even after controlling for government policy, geographical location, and other factors which impact on economic well-being.
* One healthy year of life is gained for every $1 to $8 spent on effectively treating malaria cases, which makes the malaria treatment as cost-effective a public health investment as measles vaccinations. This analysis, carried out by Dr Ann Mills, LSHTM, demonstrates that malaria control tools and intervention strategies provide good value for money.
Key among the factors contributing to the increasing malaria mortality and morbidity is the widespread resistance of Plasmodium falciparum [the most malignant form of malaria] to conventional antimalarial drugs, such as chloroquine, sulfadoxine–pyrimethamine (SP) and amodiaquine. Multidrug-resistant falciparum malaria is widely prevalent in south-east Asia and South America. Now Africa, the continent with highest burden of malaria, is also affected. Resistance to inexpensive monotherapies such as chloroquine and SP has developed or is developing rapidly, with increased mortality as a result.There have been new drugs and drug therapies developed. The key to the new therapys is that they are quite effective against the worst cases, and when done properly these treatment protocols do not result in drug-resistant parasite:
Over the past decade, a new group of antimalarials – the artemisinin compounds, especially artesunate, artemether and dihydroartemisinin – have been deployed on an increasingly large scale. These compounds produce a very rapid therapeutic response (reduction of the parasite biomass and resolution of symptoms), are active against multidrugresistant P. falciparum, are well tolerated by the patients and reduce gametocyte carriage (and thus have the potential to reduce transmission of malaria). To date, no resistance to artemisinin or artemisinin derivatives has been reported, although some decrease in sensitivity in vitro has been detected in China and Viet Nam. If used alone, the artemisinins will cure falciparum malaria in 7 days, but studies have shown that in combination with certain synthetic drugs they produce high cure rates in 3 days with higher adherence to treatment. Furthermore, there is some evidence that use of such combinations in areas with low to moderate transmission can retard the development of resistance to the partner drug.Treatment Costs:
Because ACTs are comparatively expensive and currently available only in limited quantities, UNICEF and partners are working with global manufacturers to expand the production of high-quality ACTs so that every child and community that needs these drugs can access them readily. UNICEF is also calling on donor nations to help malaria-endemic countries pay for the new drugs. A full course treatment of Coartem, the only co-formulated ACT at this time, costs $2.40 per person -- five to ten times more than chloroquine.Huh?
Unit recurrent costs per admission in KDH [Kilifi District Hospital University of Cape Town, South Africa] ranged from US $57 for 'other' paediatric malaria to US $105 for cerebral malaria, and in MSH [Malindi Sub-district Hospital] from US $33 to US $44 for the same categoriesPerhaps I'm naive, but these costs...even the inpatient costs of the most severe cases...look manageable. Sure, there are a lot of infected individuals. But when these relatively low costs are put against a child dying every 30 seconds from a treatable disease, it's somewhat shameful the disease continues.
Insecticide treated nets costs around $3.00 each and can cut malarial infections by 50%Nets have shown efficacy in reducing the much more severe cases of malaria as well:
ITBN trial [insect treated nets] found a 41% reduction in paediatric malaria admissions.So, how does it actually pencil out when looking at eliminating malaria from Africa?
Estimated costs for universal treatment and prevention strategies in Africa would cost $3.2 Billion. Current expenditures are $600 Million, or 20% of what's needed.That's a lot of money.
I'm a very lucky person with every allergy known to man but still happy to be enjoying a wonderful life living in the best place in the world!